Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

Abstract

Both oral contraceptives reduced similarly primary dysmenorrhea, with E2/NOMAC also reducing withdrawal bleedings and being neutral on lipid metabolism.

Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)

“…This was consistent with the significant improvement in menstrual cycle-related symptoms reported by women and their physicians. The significant improvement in menstrual cycle-related symptoms, including headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance, observed at 3 months and with continued improvement to 12 months, is consistent with previous studies examining NOMAC/E2 [6,7]. The high NOMAC/E2 continuation rate is also consistent with the low frequency of AEs resulting in treatment discontinuation.…”

“…The efficacy of NOMAC/E2, as well as good menstrual cycle control, with shorter and lighter withdrawal bleedings and absence of withdrawal bleeding for some women, has been demonstrated in randomised, open-label, multicentre trials that compared NOMAC/E2 with a drospirenone/EE 21/7 day regimen [4,5]. NOMAC/E2 has also been associated with reduced premenstrual and menstrual symptoms and menstrual cramping [6,7], as well as improved quality of life [7,8]. NOMAC/E2 contraceptive efficacy was maintained with less stringent back-up requirements following missed pills, likely related to the long half-life of NOMAC (46 h) and the 24/4 day regimen of NOMAC/E2 [4,5].…”

<p>Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study</p>

“…Researchers found that the monophasic regimen was associated with significant increases in overall scores, as well as the physical and mental domains. 29 According to a study that established the minimal clinically important differences (MCID) for validated QoL instruments among patients with advanced cancer and painful bone metastases, the MCID (using a distribution-based method) was 0.3 SDs for improvement and 0.5 SDs for deterioration. 30 An improvement of 0.3 SDs is equivalent to 3 points in the SF-36v2.…”

Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle?

“…Theoretically, products containing E2 should be associated with less cardiovascular events in comparison to those containing EE [8]: indeed, the impact of these new preparations on secondary minor metabolic end-points, such as lipid and glucose metabolism [9][10][11][12][13], the hemostatic system [9,10,14] and blood pressure [15] seems milder than that caused by EE-based ones. However, population data were missing.…”